First Efficacy Study for Janssen's Mosaic HIV-1 Preventive Vaccine Starting
Proof-of-concept trialing will soon begin for Janssen's promising HIV-1 prophylactic vaccine, with backing from the Gates Foundation and the NIH.
You may also be interested in...
ViiV and Merck are looking to novel mechanisms of action as an opportunity to make up ground on HIV leader Gilead, which has de-emphasized early virology research.
AstraZeneca will take Redx's RXC006 into clinical development, targeting fibrotic diseases, giving valuable credibility to the biotech’s Wnt pathway hypothesis.
Monjuvi’s good efficacy and safety profile should enable its broad adoption in the second line DLBCL space and help it compete well against rival CAR-T therapies, analysts said.